These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 20039399)

  • 1. Somatic mutations and anti-mutated citrullinated vimentin antibodies in rheumatoid arthritis: comment on the editorial by Levesque et al.
    Firestein GS
    Arthritis Rheum; 2010 Jan; 62(1):303-4. PubMed ID: 20039399
    [No Abstract]   [Full Text] [Related]  

  • 2. Selected cyclic citrullinated peptides derived from the sequence of mutated and citrullinated vimentin (MCV) are targeted by different antibodies subclasses in patients with rheumatoid arthritis in Russian patients.
    Derganova O; Martinez-Gamboa L; Egerer K; Bang H; Fredenhagen G; Roggenbuck D; Esaulenko I; Burmester GR; Chernykh T; Feist E
    Clin Exp Rheumatol; 2014; 32(5):622-9. PubMed ID: 25189876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibodies to several citrullinated antigens are enriched in the joints of rheumatoid arthritis patients.
    Snir O; Widhe M; Hermansson M; von Spee C; Lindberg J; Hensen S; Lundberg K; Engström A; Venables PJ; Toes RE; Holmdahl R; Klareskog L; Malmström V
    Arthritis Rheum; 2010 Jan; 62(1):44-52. PubMed ID: 20039432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative analysis of autoantibodies targeting peptidylarginine deiminase type 4, mutated citrullinated vimentin and cyclic citrullinated peptides in rheumatoid arthritis: associations with cytokine profiles, clinical and genetic features.
    Reyes-Castillo Z; Palafox-Sánchez CA; Parra-Rojas I; Martínez-Bonilla GE; del Toro-Arreola S; Ramírez-Dueñas MG; Ocampo-Bermudes G; Muñoz-Valle JF
    Clin Exp Immunol; 2015 Nov; 182(2):119-31. PubMed ID: 26149185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Meta-analysis: diagnostic value of serum anti-mutated citrullinated vimentin antibodies in patients with rheumatoid arthritis.
    Qin X; Deng Y; Xu J; Li TJ; Li S; Zhao JM
    Rheumatol Int; 2011 Jun; 31(6):785-94. PubMed ID: 20221607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis.
    van der Linden MP; van der Woude D; Ioan-Facsinay A; Levarht EW; Stoeken-Rijsbergen G; Huizinga TW; Toes RE; van der Helm-van Mil AH
    Arthritis Rheum; 2009 Aug; 60(8):2232-41. PubMed ID: 19644872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic value of anti-mutated citrullinated vimentin in comparison to anti-cyclic citrullinated peptide and anti-viral citrullinated peptide 2 antibodies in rheumatoid arthritis: an Italian multicentric study and review of the literature.
    Bartoloni E; Alunno A; Bistoni O; Bizzaro N; Migliorini P; Morozzi G; Doria A; Mathieu A; Lotzniker M; Allegri F; Riccieri V; Alpini C; Gabrielli A; Tampoia M; Gerli R;
    Autoimmun Rev; 2012 Sep; 11(11):815-20. PubMed ID: 22394488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of anti-mutated citrullinated vimentin, anti-cyclic citrullinated peptides, anti-glucose-6-phosphate isomerase and anti-keratin antibodies and rheumatoid factor in the diagnosis of rheumatoid arthritis in Chinese patients.
    Zhu T; Feng L
    Int J Rheum Dis; 2013 Apr; 16(2):157-61. PubMed ID: 23773638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of anti-citrullinated vimentin and anti-citrullinated α-enolase antibodies with subsets of rheumatoid arthritis.
    Montes A; Perez-Pampin E; Calaza M; Gomez-Reino JJ; Gonzalez A
    Arthritis Rheum; 2012 Oct; 64(10):3102-10. PubMed ID: 22674012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic value of anti-modified citrullinated vimentin in rheumatoid arthritis.
    Maraina CH; Nurdayana AK; Rusni D; Azwany Y
    Int J Rheum Dis; 2010 Oct; 13(4):335-9. PubMed ID: 21199468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Value of anti-mutated citrullinated vimentin antibodies in diagnosing rheumatoid arthritis.
    Sghiri R; Bouajina E; Bargaoui D; Harzallah L; Fredj HB; Sammoud S; Ghedira I
    Rheumatol Int; 2008 Nov; 29(1):59-62. PubMed ID: 18496693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Presence and diagnostic performances of IgA class antibodies to mutated citrullinated vimentin in rheumatoid arthritis.
    Sghiri R; Khalifa O; Bouajina E; Ben Haj Slama F; Baccouche K; Ben Fredj H; Gaha R; Boukadida J
    Joint Bone Spine; 2010 May; 77(3):279-80. PubMed ID: 20378382
    [No Abstract]   [Full Text] [Related]  

  • 13. Rheumatoid arthritis specific anti-Sa antibodies target citrullinated vimentin.
    Vossenaar ER; Després N; Lapointe E; van der Heijden A; Lora M; Senshu T; van Venrooij WJ; Ménard HA
    Arthritis Res Ther; 2004; 6(2):R142-50. PubMed ID: 15059278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of anti-cyclic citrullinated peptide and anti-Sa/citrullinated vimentin autoantibodies in rheumatoid arthritis.
    Rodríguez-Mahou M; López-Longo FJ; Sánchez-Ramón S; Estecha A; García-Segovia A; Rodríguez-Molina JJ; Carreño L; Fernández-Cruz E
    Arthritis Rheum; 2006 Aug; 55(4):657-61. PubMed ID: 16874789
    [No Abstract]   [Full Text] [Related]  

  • 15. Identification of citrullinated vimentin peptides as T cell epitopes in HLA-DR4-positive patients with rheumatoid arthritis.
    Feitsma AL; van der Voort EI; Franken KL; el Bannoudi H; Elferink BG; Drijfhout JW; Huizinga TW; de Vries RR; Toes RE; Ioan-Facsinay A
    Arthritis Rheum; 2010 Jan; 62(1):117-25. PubMed ID: 20039411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibodies against citrullinated vimentin in rheumatoid arthritis: higher sensitivity and extended prognostic value concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptides.
    Mathsson L; Mullazehi M; Wick MC; Sjöberg O; van Vollenhoven R; Klareskog L; Rönnelid J
    Arthritis Rheum; 2008 Jan; 58(1):36-45. PubMed ID: 18163519
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical evaluation of anti-mutated citrullinated vimentin by ELISA in rheumatoid arthritis.
    Soós L; Szekanecz Z; Szabó Z; Fekete A; Zeher M; Horváth IF; Dankó K; Kapitány A; Végvári A; Sipka S; Szegedi G; Lakos G
    J Rheumatol; 2007 Aug; 34(8):1658-63. PubMed ID: 17611988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-citrullinated protein antibodies in rheumatoid arthritis: as good as it gets?
    Szekanecz Z; Soós L; Szabó Z; Fekete A; Kapitány A; Végvári A; Sipka S; Szücs G; Szántó S; Lakos G
    Clin Rev Allergy Immunol; 2008 Feb; 34(1):26-31. PubMed ID: 18270854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibodies against mutated citrullinated vimentin are a better predictor of disease activity at 24 months in early rheumatoid arthritis than antibodies against cyclic citrullinated peptides.
    Innala L; Kokkonen H; Eriksson C; Jidell E; Berglin E; Dahlqvst SR
    J Rheumatol; 2008 Jun; 35(6):1002-8. PubMed ID: 18398946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The anti-mutated citrullinated vimentin response classifies patients with rheumatoid arthritis into broad and narrow responders.
    Engelmann R; Brandt J; Eggert M; Karberg K; Krause A; Neeck G; Mueller-Hilke B
    J Rheumatol; 2009 Dec; 36(12):2670-4. PubMed ID: 19884278
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.